Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)

Annals of the Rheumatic Diseases

Volumn 69, Issue 3, 2010, Pages 522-528

  Dixon, W G ^a   Hyrich, K L ^a   Watson, K D ^a   Lunt, M ^a   Galloway, J ^a   Ustianowski, A ^b   Symmons, D P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETHAMBUTOL; INFLIXIMAB; ISONIAZID PLUS RIFAMPICIN; PYRIDOXINE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949477575     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.118935     Document Type: Article

References (28)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. [see comment]. N Engl J Med 2001;345:1098-104.
3. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. [see comment]. Clin Infect Dis 2004;39:295-9.
4. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. [see comment]. Clin Infect Dis 2004;38:1261-5.
5. Wallis RS, Broder M, Wong J, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-5.
6. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis [see comment]. J Rheumatol 2002;29:667- 77.
7. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
8. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
9. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400- 11.
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
11. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
12. Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9.
13. van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39.
14. Watson K, Symmons D, Griffiths I, et al. The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64(Suppl 4):iv42-3.
15. NICE. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis.
16. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
17. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
18. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
19. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36.
20. Health Protection Agency. Tuberculosis in the UK. Annual report on tuberculosis surveillance and control in the UK. 2008. Available at http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb-C/1225268885969 (accessed November 2009).
21. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment. Thorax 2005;60:800-5.
22. Rose AM, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001;56:173-9.
23. Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
24. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92.
25. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60:1884-94.
26. Keane J. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis 2004;39:300-2.
27. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11.
28. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.